

National Imaging Associates, Inc.	
Clinical guidelines	Original Date: September 1997
PELVIS MRI	
CPT Codes: 72195, 72196, 72197, +0698T	Last Revised Date: March 2023 March
	2022
Guideline Number: NIA_CG_037	Implementation Date: January 202423

GENERAL INFORMATION

- It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.
- Where a specific clinical indication is not directly addressed in this guideline, medical necessity
 determination will be made based on widely accepted standard of care criteria. These criteria
 are supported by evidence-based or peer-reviewed sources such as medical literature, societal
 guidelines and state/national recommendations.

Note: There is no MRI Abdomen/Pelvis combo (comparable to a CT Abdomen/Pelvis) such that if imaging of both the abdomen and pelvis are indicated, two separate exams (and authorization) are required (i.e., MRI Abdomen and MRI Pelvis)

INDICATIONS FOR PELVIC MRI (Click here for Fetal MRI indications <u>indications</u>)

Initial pelvic imaging for staging of prostate cancer (if not recently performed for biopsy planning; Abdomen MRI can also be approved for staging if PSMA PET not requested)

Unfavorable intermediate risk, high risk and very high risk high-risk disease*

Gleason 8, 9 or 10 disease

o Gleason 4+3=7 disease (primary pattern 4)

^{*} National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- \bigcirc Gleason 3+4=7 disease AND PSA > 10 or clinical stage ≥ T2b
- Gleason 3+3=6 disease AND PSA > 20 or clinical stage \ge T3
- <u>> 50% cores positive for cancer in a random (non-targeted) biopsy</u>High Risk and above (T3a or higher, PSA >20*, Gleason 8-10)
- •<u>Intermediate Risk (T2b T2c or PSA 10-20* or Gleason 7) when Nomogram</u> predicts >10% probability of lymph node involvement (MSKCC/Kattan is the nomogram recommended by NCCN 20221)^{1,2}

<u>*Pelvis MRI can be approved in combination with PSMA PET (see PET GL) for initial staging if</u> meets above criteria

[★] In patients who have been on a 5-alpha reductase inhibitor (such as Proscar) in the past 12 months, an "adjusted PSA" should be used. To adjust, multiply PSA by a factor of 2 (i.e., PSA 6 on finasteride adjusts to a PSA of 12)

Known prostate cancer for workup of recurrence and response to treatment³

- Initial treatment by active surveillance (asymptomatic very low, low, or intermediate risk with expected patient survival ≥ 10 years):
 - Initial multiparametric MRI (mpMRI) for patients who chose active surveillance
 - •__mpMRI to be repeated no more than every 12 months unless clinically indicated
- Initial treatment by radical prostatectomy:
 - Failure of PSA to fall to undetectable level or PSA detectable and rising on at least 2 subsequent determinations
- •• Initial treatment radiation therapy:
 - Post-radiation therapy (Post-RT) rising PSA on at least 2 subsequent determinations or positive digital exam and is candidate for local therapy

Indication for prostate MRI (suspected prostate cancer)⁴⁻⁹

- ••_Prior to prostate biopsy when notes indicate that biopsy is planned¹⁰
- In individuals with previous negative biopsy and ongoing concerns of increased risk of prostate cancer (i.e., rising or persistent<u>ly</u> elevated PSA with lab reports on 2 or more separate days. OR suspicious digital rectal exam (DRE))
- When the MRI is requested to potentially avoid a prostate biopsyFor evaluation of elevated PSA (on two separate levels) when PI-RADS classification needed to make decision on whether or not to perform a biopsy when ALL of the following has been provided¹¹:
 - o Digital rectal examination (DRE) findings
 - o PSA elevation not attributed to benign disease
 - Biopsy has been discussed with the patient +
 - If there are risk factors/comorbidities associated with the biopsy, AND there is intent to biopsy if a high-risk lesion is seen on MRI prostate OR

Page 2 of 31 Pelvis MRI



- If a thorough risk assessment has been done and the patient is considered low risk for cancer AND the PIRADS classification would be used to help risk stratify the patient before making a final decision on biopsy. (Typically, this risk assessmentrequest would be done by from the person performing the biopsy (i.e., urologist) and imaging done at the facility where the fusion biopsy would be performed should a higher risk lesion be identified.)
- For evaluation of a very suspicious prostate nodule on exam when biopsy is under consideration¹¹
- Follow up MRI can be approved at the following intervals^{12, 13}:
 - o PI-RADS 3-5 lesions: 12 month 12-month interval
 - o PI-RADS 1-2 lesions: 24 month 24-month interval
 - Earlier for PI-RADS 1-2 if biopsy is clearly planned, progressive rise in PSA or other risk factors exist

Evaluation<u>of</u> of suspicious masses seen on ultrasound or CT for further evaluation of indeterminate or questionable findings: or known mass/tumors for further evaluation of indeterminate or questionable findings

- Initial imaging (see organ specific guidance below)Initial evaluation of suspicious pelvic masses/tumors found only in the pelvis by physical exam or imaging study, such as ultrasound (US), or CT¹⁰
- •----
- Further evaluation of abnormality seen on ultrasound (US) or when US is inconclusive¹¹
- Surveillance: One follow-up exam to ensure no suspicious change has occurred in a tumor in the pelvis. No further surveillance MR unless tumor(s) is/are specified as highly <u>suspicious</u> or change was found on exam or last follow-up imaging. <u>Initial staging of known cancer</u>
- •

Page **3** of **31** Pelvis MRI

- Follow-up-of-known-cancer^{2,12}:
- Of patient undergoing active treatment within the past year
- With suspected pelvic metastasis based on a sign, symptom, (e.g., anorexia, early satiety, intestinal obstruction, night sweats, pelvic pain, weight loss, vaginal bleeding) or an abnormal lab value (alpha fetoprotein, CEA, CA 19-9, p53 mutation)
- •• For abnormal incidental pelvic lymph nodes when follow-up is recommended based on prior imaging (initial 3-month follow-up)⁴

Initial staging of known cancer



Follow-up of known cancer^{3, 14}:

- In a patient undergoing active treatment within the past year or as per surveillance imaging guidance for that cancer
- With suspected pelvic metastasis based on a sign, symptom, (e.g., anorexia, early satiety, intestinal obstruction, night sweats, pelvic pain, weight loss, vaginal bleeding) or an abnormal lab value (alpha-fetoprotein, CEA, CA 19-9, p53 mutation)

Indication for combination studies for the initial pre-therapy staging of cancer, OR active monitoring for recurrence as clinically indicated OR evaluation of suspected metastases

• ≤ 5 concurrent studies to include CT or MRI of any of the following areas as appropriate depending on the cancer: Neck, Abdomen, Pelvis, Chest, Brain, Cervical Spine, Thoracic Spine or Lumbar Spine

For evaluation of suspected infection or inflammatory disease after preliminary imaging (such as CT, US, or nuclear medicine) has been performed or is contraindicated (includes MR urography (MRU) which includes abdomen MRI when indicated)¹⁵⁻¹⁸

- ••_Suspected perianal fistula
- Suspected infection (based on elevated WBC, fever, anorexia, or nausea and vomiting) in the pelvis
- •• For suspected urethral stricture or periurethral pathology¹⁹
- Suspected peritonitis (would typically need to include MRI Abdomen), abdominal pain and tenderness to palpation is present, and at LEAST one of the following:
 - Rebound, guarding or rigid abdomen, OR
 - o Severe tenderness to palpation over the entire abdomen
- Complications of diverticulitis with severe abdominal pain or severe tenderness or mass, not responding to antibiotic treatment (prior imaging study is not required for diverticulitis diagnosis)

For evaluation of known infection or inflammatory disease follow-up^{16, 20, 21}

- Any known infection that is clinically suspected to have created an abscess in the pelvis and preliminary imaging has been performed or is contraindicated
- •• Any history of fistula limited to the pelvis that requires re-evaluation or is suspected to have recurred
- •• For patients with recurrent fistula_-in-ano-or perianal Crohn's disease
- Abnormal fluid collection seen on prior imaging that needs follow-up evaluation and is limited to the pelvis

Page 4 of 31 Pelvis MRI For evaluation <u>of</u> of suspected inflammatory bowel disease<u>Inflammatory Bowel Disease (IBD)</u> <u>such as Chrohn's or Ulcerative Colitis</u> or follow-up(includes MR enterography and can also approve Abdomen MRI/MRE)

- For suspected inflammatory bowel disease after complete work up including physical exam, labs, and recent colonoscopy²²⁻²⁴
- •
- Known inflammatory bowel disease with recurrence or worsening signs/symptoms requiring re-evaluation or for monitoring therapy²⁵

For suspected inflammatory bowel disease (Crohn's disease or ulcerative colitis) with abdominal pain **AND** one of the following¹⁸⁻²⁰:

- ⊖ Chronic diarrhea
- ⊖ Bloody diarrhea
- High clinical suspicion after complete work-up including physical exam, labs, endoscopy with biopsy¹⁸⁻²¹
- Known inflammatory bowel disease (Crohn's or ulcerative colitis) with signs/symptoms (e.g., abdominal pain, diarrhea, or hematochezia) requiring re-evaluation, or for monitoring therapy¹⁸

For suspected or known hernia

- For pelvic pain due to a suspected occult, spigelian, or incisional hernia when physical exam and prior imaging (ultrasound AND CT) are non-diagnostic or equivocal²⁶⁻²⁹ and limited to the pelvis
- Hernia with suspected complications, such as strangulation or incarceration, based on physical exam (guarding, rebound) or prior imaging³⁰ (CT preferred)
- Suspected athletic pubalgia (sports hernia) in a patient with persistent groin pain that occurs with exertion, who has not responded to conservative treatment for four weeks, when other imaging is inconclusive^{31, 32}
- <u>Deep pelvic hernia is suspected (obturator, sciatic or perineal) (does not require US first</u> but this type of hernia needs to be specified in notes)³³

Indications for Musculoskeletal Pelvic MRI

Initial evaluation of suspicious mass/tumor of the bones, muscles or soft tissues of the pelvis found on an imaging study, and needing clarification, or found by physical exam and after x-ray or ultrasound is completed

- Evaluation of suspected fracture and/or injury when initial imaging is completed or for confirmed stress (fatigue) fracture for "return to play" evaluation³⁴
- For evaluation of known or suspected aseptic/avascular necrosis of hip(s) after completion of initial x-ray³⁵
- Known or suspected sacroiliitis (infectious or inflammatory) after abnormal completion of x-ray³⁶ and rheumatologic workup
- Sacroiliac Joint Dysfunction (after initial X-ray) when there is³⁶:
 - Persistent back and/or sacral pain unresponsive to four (4) weeks of conservative treatment, received within the past six (6) months, including physical therapy or physician supervised home exercise plan (HEP)
- •• For evaluating the lumbosacral plexus^{37, 38}:
 - \circ To confirm involvement in symptomatic patients with known tumor
 - To assess extent of injuries in the setting of pelvic trauma
 - To exclude the presence of masses in patients with unilateral changes, or inconclusive or abnormal findings on EMG when there are persistent symptoms
 - \circ For evaluation when lumbar spine MRI is suspicious or indeterminate
- For suspicion of pudendal neuralgia in the setting of chronic pelvic pain with genital numbness and erectile dysfunction when other causes have been ruled out (see <u>Background</u> regarding diagnosis)³⁹

••_For suspicion of meralgia paresthetica when prior testing is inconclusive (diagnostic nerve block; electrodiagnostic testing; AND somatosensory evoked potentials)^{40, 41}

- ••_Persistent Pain:
 - For evaluation of persistent pain unresponsive to four (4) weeks of conservative treatment received within the past six (6) months
 - For suspected piriformis syndrome after failure of 4 weeks conservative treatment⁴²
- For evaluation of both hips when the patient meets hip MRI guidelines (x-ray + persistent pain unresponsive to conservative treatment) for both the right and left hip, Pelvis MRI is the preferred study.
 - If labral tear is suspected due to a positive anterior impingement sign or posterior impingement sign, then bilateral hip MRIs are the preferred studies (not Pelvis MRI)
 - If bilateral hip arthrograms are requested and otherwise meet guidelines, bilateral hip MRIs are the preferred studies (not Pelvis MRI)
- For further evaluation of congenital anomalies of the sacrum and pelvis and initial imaging has been performed

For evaluation of known or suspected non-aortic vascular disease (e.g., aneurysms, hematomas)^{43, 44}, CTA/MRA is the preferred study when ultrasound is inconclusive

If a contraindication to CTA/MRA has been provided, MRI can be approved



Other Indications for a Pelvic MRI when CT is inconclusive or cannot be completed

- Persistent abdominal/pelvic pain not explained by previous imaging
- For any of the following B symptoms: fevers more than 101° F, drenching night sweats, or unexplained weight loss of more than 10% of body weight over 6 months with documented concern for lymphoma/malignancy when CT is inconclusive or cannot be completed (can approve abdomen MRI, too, when appropriate)
- Clinically significant unintentional weight loss i.e., ≥ 5% of body weight in less than 12 months (or ≥ 2% in one month), with signs or symptoms suggestive of an abdominal cause (see Background for {wWeight loss definitions and initial evaluation}, Abdomen MRI should also be approved)
- Ongoing unexplained clinically significant weight loss i.e., ≥ 5% of body weight in less than 12 months (or ≥ 2% in one month)⁴⁵⁻⁴⁷, after initial workup (see Background) has been completed, no cause identified, and second visit documenting further decline in weight (CT Chest may also be approved)
- For fever of unknown origin (temperature of ≥ 101° degrees for a minimum of 3 weeks) after standard diagnostic tests are negative⁴⁸
- For suspected or known retroperitoneal fibrosis after complete workup and ultrasound to determine extent of disease⁴⁹
- For suspected paraneoplastic syndrome (including dermatomyositis) with high suspicion of abdominal malignancy and appropriate workup has been done (see Background for details)
- For diffuse, unexplained lower extremity edema with negative or inconclusive ultrasound⁵⁰
- For suspected May-Thurner syndrome (CTV/MRV preferred)^{51, 52}
- For further evaluation of a new onset or non-reducible varicocele⁵³
- Prior to liver transplantation (Abdomen CT preferred, MRCP also approvable), may repeat studies immediately prior to transplantation with known HCC, PSC or cholangiocarcinoma
- Prior to Bone Marrow Transplant (BMT) (along with CT Chest⁵⁴, CT (or MR) Abdomen, CT Sinus and Brain MRI)⁵⁵). Alternatively, PET might be sufficient to evaluate the abdomen and pelvis if indicated based on that malignancy (see PET Guideline)
- Prior to solid organ transplantation
- Von Hippel Lindau (VHL) at least every other year starting at age 16; can also approve abdomen MRI (abdomen and pelvis ultrasound starting at age 8)⁵⁶
- Hereditary Paraganglioma syndromes every 2-3 years IF whole body MRI (unlisted MRI CPT 76498) not available. (WB MRI is the preferred study; if unable to do whole body MRI may approve abdomen MRI, pelvis MRI, skull base and neck MRI and chest CT. SDHB mutation may start at age 6, all other SDHx start at age 10).
- Multiple Endocrine Neoplasia type 1 (MEN1) every 1-3 years (chest CT or MRI also approvable for this syndrome at same interval) ⁵⁷

Other indications for a Pelvic MRI (MRI preferred over CT)

- ••_Pelvic pain not explained by previous imaging/pre_procedure⁵⁸
 - Appropriate laboratory testing (chemistry profile, complete blood count, and urinalysis) and initial imaging, such as ultrasound
- For B symptoms of fevers more than 101 F, drenching night sweats, or unexplained weight loss of more than 10% of body weight over 6 months when CT is inconclusive or cannot be completed (can approve abdomen MRI, too, when appropriate)
- For location or evaluation of undescended testes in adults and in children, including determination of location of testes, if ordered by a specialist⁵⁹
- For evaluation and characterization of uterine and adnexal masses, (e.g., fibroids, ovaries, tubes, and uterine ligaments) or congenital uterine or renal abnormality where ultrasound has been done previously⁵⁸
- For evaluation of abnormal uterine bleeding when ultrasound findings are indeterminate⁶⁰
 - Age \leq 50 Vascular stalk or focal doppler signal on US
 - Age > 50 Thickened endometrium, vascular stalk or focal doppler signal on US
- For evaluation of uterus prior to and after embolization (MRA preferred may be approved in addition to MRI for preprocedural planning)⁶¹
- For evaluation of endometriosis when preliminary imaging has been completed or to follow up known endometriosis^{62, 63}
- ••_For further evaluation of suspected adenomyosis when ultrasound is inconclusive,⁶⁴ such as the following:
 - o Uterine abnormality on US
 - Anechoic spaces/cysts in myometrium
 - Heterogeneous echotexture
 - Obscured endometrial/myometrial border
 - Sub-endometrial echogenic linear striations
 - Thickening of the transition zone
 - Uterine enlargement
 - Uterine wall thickening
- •• Prior to uterine surgery if there is abnormality suspected on prior ultrasound
- •• For suspected placenta accreta or percreta when ultrasound is indeterminate⁶⁵
- For further assessment of a scrotal or penile mass when ultrasound is inconclusive 66, 67
- •• For investigation of a malfunctioning penile prosthesis
- Suspected urethral diverticula and other imaging is inconclusive⁶⁸
 (MRI may be indicated without prior ultrasound in limited situations as suggested, such as when there is compelling evidence suggestive of urethral diverticulum (i.e., ostia on



cystoscopy or tender cystic lesion on anterior vaginal wall overlying the urethra) or for surgical planning.)

- ••_For suspected pelvic congestion syndrome in women with chronic pelvic pain when other imaging is non-diagnostic⁶⁹
- For suspected patent urachus or other urachal abnormalities when ultrasound is nondiagnostic^{70, 71}
- MR defecography for suspected structural cause of defecatory outlet obstruction to confirm diagnosis if other testing is equivocal (anorectal manometry and balloon expulsion testing)⁷²
- For evaluation of enlargement of organ abnormality seen on previous imaging to provide an alternative to an indeterminate or inconclusive ultrasound
- For diffuse, unexplained lower extremity edema with negative or inconclusive ultrasound
- For May-Thurner syndrome (MRV preferred)
- For further evaluation of an isolated right varicocele with additional signs and symptoms that suggest malignancy or suspicious prior imaging findings⁵³
- Surveillance MRI (include abdomen) every 2-3 years for patients with Hereditary Paraganglioma syndromes Type 1-5⁷³
- For transient or episodic hematospermia and age ≥ 40 with negative or inconclusive ultrasound
- - For persistent hematospermia (duration > 1 month, any age) with negative or inconclusive ultrasound in hematospermia in men over 40, if transrectal ultrasound is negative or inconclusive⁷⁴
- •

Other Indications

<u>Further evaluation of indeterminate findings on prior imaging (unless follow up is otherwise</u> <u>specified within the guideline):</u>

- For initial evaluation of an inconclusive finding on a prior imaging report that requires further clarification
- One follow-up exam of a prior indeterminate MR/CT finding to ensure no suspicious interval change has occurred. (No further surveillance unless specified as highly suspicious or change was found on last follow-up exam)

Pre-operative evaluation

•• For diagnostic purposes prior to pelvic surgery or procedure

Post-operative/procedural evaluation

Page **9** of **31** Pelvis MRI



- Follow-up of known or suspected post-operative complication involving the hips or the pelvis^{75, 76} within six months
- A follow-up study to help evaluate a patient's progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed.

Note: If an Abdomen/Pelvis MRI is indicated and the Abdomen MRI has already been approved, then the Pelvis MRI may be approved.

Fetal MRI (CPT codes 74712-74713) - To better define or confirm a known for suspected abnormality of the fetus after ultrasound has been performed during the second trimester⁷⁷ or when fetal surgery is planned and/or to make a decision about therapy, delivery or to advise the family about prognosis.⁷⁸ Also includes evaluation of the maternal pelvis and placenta.

BACKGROUND

Magnetic resonance imaging of the pelvis is a noninvasive technique for the evaluation, assessment of severity, and follow-up of diseases of the male and female pelvic organs. MRI provides excellent contrast of soft tissues and provides multiplanar and 3D depiction of pathology and anatomy. Patients undergoing MRI do not have exposure to ionizing radiation or iodinated contrast materials. MRI techniques utilize body coils to image the entire pelvis or endoluminal coils for evaluation of the rectum, prostate, and genitourinary system.

OVERVIEW

PI-RADS Assessment Categories for Prostate Cancer⁷⁹:

The assignment of a PI-RADS category is based on mpMRI findings only and does not incorporate other factors, including PSA testing, DRE (digital rectal exam), or clinical history.

- PI-RADS 1 Very low (clinically significant cancer is highly unlikely to be present)
- PI-RADS 2 Low (clinically significant cancer is unlikely to be present)
- PI-RADS 3 Intermediate (the presence of clinically significant cancer is equivocal)
- PI-RADS 4 High (clinically significant cancer is likely to be present)
- PI-RADS 5 Very high (clinically significant cancer is highly likely to be present)

*Conservative Therapy – Conservative therapy should include a multimodality approach consisting of a combination of active and inactive components. Inactive components, such as

Page **10** of **31** Pelvis MRI



rest, ice, heat, modified activities, medical devices, acupuncture and/or stimulators, medications, injections (epidural, facet, bursal, and/or joint, not including trigger point), and diathermy can be utilized. Active modalities may consist of physical therapy, a physician-supervised home exercise program**, and/or chiropractic care.

****Home Exercise Program - (HEP)/Therapy** – the following elements are required to meet guidelines for completion of conservative therapy^{80, 81}:

- Information provided on exercise prescription/plan AND
- Follow up with member with documentation provided regarding lack of improvement (failed) after completion of HEP (after suitable 4-week period), or inability to complete HEP due to physical reason- i.e., increased pain, inability to physically perform exercises. (Patient inconvenience or noncompliance without explanation does not constitute "inability to complete" HEP).
- Dates and duration of failed PT, physician-supervised HEP, or chiropractic treatment should be documented in the original office notes or an addendum to the notes.

MRI and Undescended Testes – The most common genital malformation in boys is undescended testis. In one series, 70% of undescended testes are palpable. Despite the advances in ultrasound technology, ultrasound cannot reliably identify intra-abdominal testes, which comprise 20% of all undescended testes.⁸² The timely management of undescended testis is important to potentially minimize the risk of infertility and lessen the risk of malignancy. MRI is used as a diagnostic tool in the detection of undescended testes and can reveal information for both anatomic and tissue characterization. It is noninvasive, nonionizing, and can obtain multiplanar images.

MRI and Adnexal Masses – MRI is used in the evaluation of adnexal masses. It can identify and characterize different neoplastic and nonneoplastic abnormalities, e.g., exophytic leiomyoma, endometrioma, dermoid cyst, and ovarian edema. It is a useful adjunct when sonography is inconclusive in the evaluation of adnexal masses.

MRI and Endometriosis – MRI manifestations of endometriosis vary including endometrioma, peritoneal endometrial implant, adhesion, and other rare features. The data obtained from imaging must be combined with clinical data to perform preoperative assessment of endometriosis.

MRI and Lumbosacral Plexopathy – Complete lumbar (L1-L4) or sacral plexopathy (L5-S3) may present with weakness, sensory loss, and flaccid loss of tendon reflexes. Clinical diagnosis is confirmed by EMG. Acute and chronic plexopathies may be caused by nerve sheath tumors; infectious, autoimmune, hereditary, or idiopathic neuropathies; extrinsic compression; or trauma.³⁸ There is no CPT[®] code specifically for imaging of the LS plexus.

Pudendal neuralgia may be considered in chronic pain patients who meet the Nantes criteria: pain in the area innervated by the pudendal nerve, pain more severe with sitting, pain that

Page **11** of **31** Pelvis MRI



does not awaken the patient from sleep, pain with no objective sensory impairment, and pain relieved by pudendal block. All five criteria must be met for diagnosis.³⁹

MRI and Prostate Cancer – Although prostate cancer is the second leading cause of cancer in men, most cases do not lead to a prostate cancer-related death. Aggressive treatment of prostate cancer can have side effects, such as incontinence, rectal injury, and impotence. It is very important to do an evaluation that will assist in making decisions about therapy or treatment. MRI can non-invasively assess prostate tissue, functionally and morphologically. MRI evaluation may use a large array of techniques, e.g., T1-weighted images, T2-weighted images, and dynamic contrast enhanced T1-weighted images.

Prostate Cancer – MRI is not recommended in patients with suspected cancer but prior negative biopsy because MRI alone can miss up to 26% of clinically significant cancers that would be detected on TRUS biopsy.⁵ Patients with suspected prostate cancer should first undergo a systematic biopsy and if that fails to demonstrate tumor, an MRI can then be obtained to guide future biopsy attempts.^{4,8}

Per NCCN,^{10,64} for asymptomatic patients with prostate cancer, in very low, low, or intermediate groups with life expectancy \leq 5 years, no further treatment or work-up indicated (unless the patient becomes symptomatic). Active surveillance is indicated if life expectancy is determined to be \geq 10 years.

MRI and Rectal Cancer – MRI is used in the evaluation of rectal cancer to visualize not only the intestinal wall but also the surrounding pelvic anatomy. MRI is an excellent imaging technique due to its high soft-tissue contrast, powerful gradient system, and high resolution. It provides accurate evaluation of the topographic relationship between lateral tumor extent and the mesorectal fascia.

Imaging of hernias – Most hernias are diagnosed clinically with imaging recommended for the diagnosis of occult hernias or in the evaluation of hernia complications, such as bowel obstruction or strangulation. To detect occult hernias, ultrasound is a first-line study with a sensitivity of 86% and specificity of 77%, compared to 80% sensitivity and 65% specificity for CT.²⁹ According to Miller et al, "Magnetic resonance imaging is generally not considered a first-or even second-line evaluation modality for hernias...."²⁸ Both MRI and US can be valuable for diagnosing pathology in athletes with groin pain when a sports hernia is suspected. Pain usually occurs with exertion with tenderness over the pubic symphysis or tubercle and exquisite tenderness on direct palpation of the superficial inguinal ring (positive direct stress test).This term initially denoted a posterior inguinal wall deficiency due to disruption of fascia and/or muscle but more recently given the label "core injury" to also include adductor tendon tears, injury to the aponeurosis of the rectus abdominus and adductor longus tendons, and osteitis pubis.³¹

Page **12** of **31** Pelvis MRI



Elevated CA-125 and pelvic imaging – There is no evidence that isolated levels of CA-125 with no other clinical or radiologic evidence of pathology is sensitive or specific and should not be performed as an isolated test as it can lead to unnecessary studies and anxiety. It is elevated in most cases of epithelial ovarian cancer and is used in monitoring response to treatment as an adjunct to pelvic US. CA-125 has been shown to be increased in many conditions such as fibroids, adenomyosis, pancreatic cancer, endometriosis, tuberculosis, and interstitial lung disease. MRI is not indicated as a first-line test.⁸³

Fever of Unknown Origin

Initial work up prior to CT would include a comprehensive history, repeated physical exam, complete blood count with differential, three sets of blood cultures, chest x-ray, complete metabolic panel, urinalysis, ESR, ANA, RA, CMV IgM antibodies, virus detection in blood, heterophile antibody test, tuberculin test, and HIV antibody test.⁴⁸ Lastly, with a negative CXR, only when initial workup and abdomen/pelvis CT/MR fail to identify the cause for fever can Chest CT be approved. If CXR suggests a malignancy and/or source of fever, then Chest CT would be approved.

Suspected paraneoplastic syndromes with no established cancer diagnosis: laboratory evaluation and imaging

The laboratory evaluation for paraneoplastic syndrome is complex. If the appropriate lab test results are suspicious for malignancy, imaging is indicated.

For **SIADH** (hyponatremia + increased urine osmolality), there is a high association with small cell lung cancer, therefore imaging typically starts with chest CT. If other symptoms suggest a different diagnosis other than small cell lung cancer, different imaging studies may be reasonable.

For **hypercalcemia** (high serum calcium, low-normal PTH, high PTHrP) it is reasonable to start with bone imaging followed by a more directed evaluation such as mammogram, chest, abdomen and pelvis imaging as appropriate.

For **Cushing syndrome** (hypokalemia, normal-high midnight serum ACTH NOT suppressed with dexamethasone) abdominal and chest imaging is reasonable. If dexamethasone suppression test DOES suppress ACTH, pituitary MRI is reasonable.

For **hypoglycemia**, labs drawn during a period of hypoglycemia (glucose < 55, typically a 72 hour fast) (insulin level, C-peptide and IGF-2:IGF-1 ratio) should be done to evaluate for an insulinoma. An elevated insulin level, elevated C-peptide and/or normal IGF-2:IGF-1 ratio warrant CT or MRI abdomen to look for insulinoma. A low insulin, low C-peptide and/or elevated IGF-2:IGF-1 ratio warrant chest and abdominal imaging.

When a **paraneoplastic neurologic syndrome** is suspected, nuclear and cytoplasmic antibody panels are often ordered to further identify specific tumor types. Results are needed prior to

imaging. Because these tests are highly specific, if an antibody highly associated with a specific cancer is positive, then further imaging for that cancer is reasonable. For example, anti-Hu has a high association with SCLC and chest CT would be reasonable. Anti-MA2 has a high association with testicular cancer and testicular ultrasound would be a reasonable next step.

Weight loss definitions and initial evaluation-

Unintentional weight loss is considered clinically significant if the amount of weight lost over 12 months is \geq 5%. Older age and higher percentage of weight loss correlates with higher likelihood of malignancy. A targeted evaluation is recommended when there are signs or symptoms suggestive of a specific source. For example, when there is clinically significant weight loss with abdominal pain that prompts an evaluation for an abdominal source of the weight loss; CXR and labs such as TSH would not be needed prior to abdominal imaging. Conversely a smoker with a cough and weight loss would not start with abdominal imaging, a chest x-ray (CXR) would be the first test to start with. When there is no suspected diagnosis, initial evaluation includes CXR, age-appropriate cancer screening (such as colonoscopy and mammography) and labs (including CBC, CMP, HbA1C, TSH, stool hemoccult, ESR/CRP, HIV, Hepatitis C). If this initial evaluation fails to identify a cause of weight loss, then the patient is monitored and if progressive weight loss is seen on subsequent visits/weights, then CT Abdomen/Pelvis is reasonable (MRI if there is a contraindication to CT such as contrast allergy or impaired renal function). Lastly, with a negative CXR, only when initial workup and abdomen/pelvis CT/MR fail to identify the cause for weight loss can Chest CT be approved. If CXR suggests a malignancy and/or source of weight loss, then Chest CT would be approved.

Weight loss definitions and initial evaluation - Unintentional weight loss is considered clinically significant if the amount of weight lost over 12 months is \geq 5%. Older age and higher percentage of weight loss correlates with higher likelihood of malignancy. A targeted evaluation is recommended when there are signs or symptoms suggestive of a specific source. For example, when there is clinically significant weight loss with abdominal pain that prompts an evaluation for an abdominal source of the weight loss; CXR and labs such as TSH would not be needed prior to abdominal imaging. Conversely a smoker with a cough and weight loss would not start with abdominal imaging, a chest x-ray (CXR) would be the first test to start with. When there is no suspected diagnosis, initial evaluation includes CXR, age appropriate cancer screening (such as colonoscopy and mammography) and labs (including CBC, CMP, HbA1C, TSH, stool hemoccult, ESR/CRP, HIV, Hepatitis C). If this initial evaluation fails to identify a cause of weight loss, then the patient is monitored and if progressive weight loss is seen on subsequent visits/weights, then CT Abdomen/Pelvis is reasonable (MRI if there is a contraindication to CT such as contrast allergy or impaired renal function). Lastly, with a negative CXR, only when initial workup and abdomen/pelvis CT/MR fail to identify the cause for weight loss can Chest CT be approved. If CXR suggests a malignancy and/or source of weight loss, then Chest CT would be approved.

POLICY HISTORY

Date	Summary
2023	
March 2022	 Added when MRI is requested to potentially avoid a prostate biopsy
	 Added abnormal incidental pelvic lymph nodes when follow-up is
	recommended based on prior imaging (initial 3-month follow-up)
	Within section concerning evaluation of suspected infection or inflammatory disease_added:
	Suspected peritonitis (typically needing to include MRI Abd)
	with abd pain, tenderness to palpation, and at least one of the
	following:
	 Rebound, guarding or rigid abdomen, OR
	 Severe tenderness to palpation over entire abdomen
	 Complications of diverticulitis with severe abdominal pain or
	severe tenderness or mass, not responding to antibiotic
	treatment (prior imaging study is not required for diverticulitis
	diagnosis)
	 Removed "For MR Enterography (MRE) if CT or MRI of the
	abdomen and pelvis are inconclusive" from the section on
	evaluation of suspected IBD
	 Clarified pelvic pain due to suspected occult, spigelian, or incisional hernia
	 Clarified hernia with suspected complications
	 Added "after initial x ray" to Sacroiliac Joint Dysfunction
	Removed "For evaluation of suspected pelvic floor weakness in
	women with functional disorders, such as urinary or fecal
	incontinence, obstructed defecation, and pelvic organ prolapse"
	from "Other Indications for a Pelvic MRI"
	 Added B symptoms to "Other Indications for a Pelvic MRI"
November 2021	Added +0698T
July 2021	Clarified language in Indication for prostate MRI (suspected
	prostate cancer) based on updates to Version 2.2021 NCCN
	guidelines and 2020 publication of updated AUA SAR SOPs
	regarding MRI
April 2021	 Updated the initial imaging for prostate cancer to reflect 2021 NCCN changes and "adjusted PSA"

	 Revised indication for prostate MRI (suspected prostate cancer) to
	clarify criteria related to a negative prior biopsy and added criteria
	for when imaging is appropriate prior to biopsy
	 Included criteria for ultrasound abnormalities for adenomyosis
	 Added limited circumstances when prior imaging is not needed
	before MRI for the evaluation of urethral diverticula
May 2020	Mention MRU which includes MRI abd
	 Perianal fistula including with Crohn's
	Urethral eval
	Added section on MRE for IBD
	 Added section on Lumbosacral plexus, pudendal neuralgia.
	maralgia paresthetica, piriformis syndrome
	 Added separate section on hernia including sports hernia
	Added abnormal uterine bleeding: adenomyosis: pelvic floor
	weakness: urachal anomalies: MR defecography: surveillance for
	paraganglioma syndromes; hematospermia; LE edema; right
	varicocele; May-Thurner
	Added the Fetal MR GL to page
	 Comment section on Lumbar plexopathy, sports hernia, elevated
	СА-125
June 2019	 Added the following indications:
	 rising or persistent elevated PSA OR suspicious DRE and at
	least 15 years life expectancy and negative prior biopsy
	\sim suspected periodal fistula
	\sim 6 months time specification for f/u of known or suspected
	nost operative complication involving hins or polvic
	post-operative complication involving mps or pervis
	Tor commed stress (ratigue) fracture for return to play
	evaluation
	 post operative complications after pelvic floor surgery
	 For known prostate cancer: Initial treatment by active
	surveillance w/initial mpMRI and mpMRI to be repeated no
	more than every 12 months unless clinically indicated
	 suspected placenta accrete or percreta when US is
	indeterminate
	 further assessment of a scrotal or penile mass when
	ultrasound is inconclusive
1	 investigation of a malfunctioning popula prosthosic



 suspected urethral diverticula and other imaging is
inconclusive
\circ evaluation of adenomyosis when ultrasound is equivocal,
especially in the case of suspected focal adenomyoma when it
will help determine if surgery is indicated
 suspected pelvic congestion syndrome in patients with chronic
pelvic pain when other imaging is non-diagnostic
 suspected patent urachus when ultrasound is non diagnostic
 evaluation of enlargement of organ abnormality seen on
previous imaging - to provide an alternative to an
indeterminate or inconclusive ultrasound
 PI-RADS information to background section
• Home exercise program information updated to include dates
and duration of failed PT and other



REFERENCES

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) Prostate Cancer NCCN Evidence Blocks (tm) Version 1.2023. National Comprehensive Cancer Network. Updated November 4, 2022. Accessed December 17, 2022.

https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf

 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer Version 1.2023. National Comprehensive Cancer Network (NCCN). Updated September 16, 2022. Accessed March 2, 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
 NCCN Imaging Appropriate Use Criteria[™]. National Comprehensive Cancer Network (NCCN). Accessed January 31, 2023. https://www.nccn.org/professionals/imaging/default.aspx
 Bjurlin MA, Carroll PR, Eggener S, et al. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. *J Urol*. Apr 2020;203(4):706-712. doi:10.1097/ju.00000000000617

5. Fulgham PF, Rukstalis DB, Rubenstein JN, et al. Standard Operating Procedure for Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer: A Collaborative Initiative by the American Urological Association and the Society of Abdominal Radiology Prostate Disease Focus Panel. American Urological Association. Updated May 2019. Accessed December 28, 2022. https://www.auanet.org/guidelines-andquality/guidelines/other-clinical-guidance/mri-of-the-prostate-sop

6. Borofsky S, George AK, Gaur S, et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. *Radiology*. Jan 2018;286(1):186-195. doi:10.1148/radiol.2017152877

7. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. *Eur Urol*. Feb 2021;79(2):263-282. doi:10.1016/j.eururo.2020.09.046

8. Mottet N, Bellmunt J, Briers E, et al. EAU–ESTRO–ESUR–SIOG guidelines on prostate cancer. European Association of Urology. Updated 2022. Accessed December 15, 2022. https://uroweb.org/guidelines/prostate-cancer

9. Elkhoury FF, Felker ER, Kwan L, et al. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. *JAMA Surg*. Sep 1 2019;154(9):811-818. doi:10.1001/jamasurg.2019.1734

10. Alexander LF, Oto A, Allen BC, et al. ACR Appropriateness Criteria[®] Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia. *J Am Coll Radiol*. Nov 2019;16(11s):S378-s383. doi:10.1016/j.jacr.2019.05.031

11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer Early Detection Version 1.2023. National Comprehensive Cancer Network (NCCN). Updated January 9, 2023. Accessed March 2, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf



12. Boschheidgen M, Schimmöller L, Doerfler S, et al. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate. *Sci Rep.* Apr 25 2022;12(1):6746. doi:10.1038/s41598-022-10859-9

13. Schoots IG. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? *Transl Androl Urol.* Feb 2018;7(1):70-82. doi:10.21037/tau.2017.12.31

 Bourgioti C, Chatoupis K, Moulopoulos LA. Current imaging strategies for the evaluation of uterine cervical cancer. *World J Radiol*. Apr 28 2016;8(4):342-54. doi:10.4329/wjr.v8.i4.342
 Cartwright SL, Knudson MP. Diagnostic imaging of acute abdominal pain in adults. *Am Fam Physician*. Apr 1 2015;91(7):452-9.

16. American College of Radiology. ACR Appropriateness Criteria[®] Anorectal Disease. American College of Radiology (ACR). Updated 2021. Accessed December 17, 2022.

https://acsearch.acr.org/docs/3102384/Narrative/

17. American College of Radiology. ACR Appropriateness Criteria[®] Left Lower Quadrant Pain-Suspected Diverticulitis. American College of Radiology. Updated 2018. Accessed December 17, 2022. https://acsearch.acr.org/docs/69356/Narrative/

18. American College of Radiology. ACR Appropriateness Criteria® Soft-Tissue Masses.

American College of Radiology. Updated 2022. Accessed January 23, 2023.

https://acsearch.acr.org/docs/69434/Narrative/

19. Aldamanhori R, Inman R. The treatment of complex female urethral pathology. *Asian J Urol*. Jul 2018;5(3):160-163. doi:10.1016/j.ajur.2018.03.003

20. Vogel JD, Johnson EK, Morris AM, et al. Clinical Practice Guideline for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. *Dis Colon Rectum*. Dec 2016;59(12):1117-1133. doi:10.1097/dcr.0000000000000733

21. American College of Radiology. ACR Appropriateness Criteria[®] Crohn Disease. American College of Radiology. Updated 2019. Accessed November 20, 2022.

https://acsearch.acr.org/docs/69470/Narrative/

22. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol*. Mar 2019;114(3):384-413. doi:10.14309/ajg.00000000000152

23. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. Apr 2018;113(4):481-517. doi:10.1038/ajg.2018.27

24. Arif-Tiwari H, Taylor P, Kalb BT, Martin DR. Magnetic resonance enterography in inflammatory bowel disease. *Applied Radiology*. 2019;48(1):9-16.

25. American College of Radiology. ACR Appropriateness Criteria[®] Crohn Disease. American College of Radiology. Updated 2019. Accessed November 15, 2022.

https://acsearch.acr.org/docs/69470/Narrative/

26. Bedewi MA, El-sharkawy M. Imaging of Hernias. Hernia. 2017;30:31.

27. Lassandro F, Iasiello F, Pizza NL, et al. Abdominal hernias: Radiological features. *World J Gastrointest Endosc*. Jun 16 2011;3(6):110-7. doi:10.4253/wjge.v3.i6.110



28. Miller J, Cho J, Michael MJ, Saouaf R, Towfigh S. Role of imaging in the diagnosis of occult hernias. *JAMA Surg*. Oct 2014;149(10):1077-80. doi:10.1001/jamasurg.2014.484

29. Robinson A, Light D, Kasim A, Nice C. A systematic review and meta-analysis of the role of radiology in the diagnosis of occult inguinal hernia. *Surg Endosc*. Jan 2013;27(1):11-8. doi:10.1007/s00464-012-2412-3

30. Halligan S, Parker SG, Plumb AAO, et al. Use of imaging for pre- and post-operative characterisation of ventral hernia: systematic review. *Br J Radiol*. Sep 2018;91(1089):20170954. doi:10.1259/bjr.20170954

 Lee SC, Endo Y, Potter HG. Imaging of Groin Pain: Magnetic Resonance and Ultrasound Imaging Features. *Sports Health*. Sep/Oct 2017;9(5):428-435. doi:10.1177/1941738117694841
 Paksoy M, Sekmen Ü. Sportsman hernia; the review of current diagnosis and treatment modalities. *Ulus Cerrahi Derg*. 2016;32(2):122-9. doi:10.5152/ucd.2015.3132

33. American College of Radiology. ACR Appropriateness Criteria[®] Hernia. American College of Radiology. Updated 2022. Accessed March 2, 2023.

https://acsearch.acr.org/docs/3158169/Narrative/

34. American College of Radiology. ACR Appropriateness Criteria[®] Stress (Fatigue/Insufficiency)
Fracture, Including Sacrum, Excluding Other Vertebrae. American College of Radiology (ACR).
Updated 2016. Accessed December 28, 2022. https://acsearch.acr.org/docs/69435/Narrative/
35. American College of Radiology. ACR Appropriateness Criteria[®] Osteonecrosis of the Hip.
American College of Radiology. Updated 2022. Accessed December 28, 2022.

https://acsearch.acr.org/docs/69420/Narrative/

36. Jans L, Van Praet L, Elewaut D, et al. MRI of the SI joints commonly shows noninflammatory disease in patients clinically suspected of sacroiliitis. *Eur J Radiol*. Jan 2014;83(1):179-84. doi:10.1016/j.ejrad.2013.10.001

37. Muniz Neto FJ, Kihara Filho EN, Miranda FC, Rosemberg LA, Santos DCB, Taneja AK. Demystifying MR Neurography of the Lumbosacral Plexus: From Protocols to Pathologies. *Biomed Res Int*. 2018;2018:9608947. doi:10.1155/2018/9608947

38. American College of Radiology. ACR Appropriateness Criteria[®] Plexopathy. American College of Radiology (ACR). Updated 2021. Accessed December 28, 2022. https://acsearch.acr.org/docs/69487/Narrative/

39. Wadhwa V, Hamid AS, Kumar Y, Scott KM, Chhabra A. Pudendal nerve and branch neuropathy: magnetic resonance neurography evaluation. *Acta Radiol.* Jun 2017;58(6):726-733. doi:10.1177/0284185116668213

40. Ally RM, Velleman MD, Suleman FE. Meralgia paresthetica: Now showing on 3T magnetic resonance neurography. *SA J Radiol*. 2019;23(1):1745. doi:10.4102/sajr.v23i1.1745

41. Cheatham SW, Kolber MJ, Salamh PA. Meralgia paresthetica: a review of the literature. *Int J Sports Phys Ther*. Dec 2013;8(6):883-93.

42. Ro TH, Edmonds L. Diagnosis and Management of Piriformis Syndrome: A Rare Anatomic Variant Analyzed by Magnetic Resonance Imaging. *J Clin Imaging Sci*. 2018;8:6. doi:10.4103/jcis.JCIS_58_17

43. Khosa F, Krinsky G, Macari M, Yucel EK, Berland LL. Managing incidental findings on abdominal and pelvic CT and MRI, Part 2: white paper of the ACR Incidental Findings Committee II on vascular findings. *J Am Coll Radiol*. Oct 2013;10(10):789-94. doi:10.1016/j.jacr.2013.05.021
44. Uberoi R, Tsetis D, Shrivastava V, Morgan R, Belli AM. Standard of practice for the interventional management of isolated iliac artery aneurysms. *Cardiovasc Intervent Radiol*. Feb 2011;34(1):3-13. doi:10.1007/s00270-010-0055-0

45. Nicholson BD, Thompson MJ, Hobbs FDR, et al. Measured weight loss as a precursor to cancer diagnosis: retrospective cohort analysis of 43 302 primary care patients. *J Cachexia Sarcopenia Muscle*. Oct 2022;13(5):2492-2503. doi:10.1002/jcsm.13051

46. Wong CJ. Involuntary weight loss. *Med Clin North Am*. May 2014;98(3):625-43. doi:10.1016/j.mcna.2014.01.012

47. Gaddey HL, Holder K. Unintentional weight loss in older adults. *Am Fam Physician*. May 1 2014;89(9):718-22.

48. Brown I, Finnigan NA. Fever of Unknown Origin. StatPearls Publishing. Updated August 22, 2022. Accessed November 19, 2022. https://www.ncbi.nlm.nih.gov/books/NBK532265/
49. Runowska M, Majewski D, Puszczewicz M. Retroperitoneal fibrosis - the state-of-the-art.

Reumatologia. 2016;54(5):256-263. doi:10.5114/reum.2016.63667

50. Hoshino Y, Machida M, Shimano Si, et al. Unilateral Leg Swelling: Differential Diagnostic Issue Other than Deep Vein Thrombosis. *Journal of General and Family Medicine*. 2016;17(4):311-314.

51. Ibrahim W, Al Safran Z, Hasan H, Zeid WA. Endovascular management of may-thurner syndrome. *Ann Vasc Dis*. 2012;5(2):217-21. doi:10.3400/avd.cr.12.00007

52. Wu WL, Tzeng WS, Wu RH, et al. Comprehensive MDCT evaluation of patients with suspected May-Thurner syndrome. *AJR Am J Roentgenol*. Nov 2012;199(5):W638-45. doi:10.2214/ajr.11.8040

53. Schlegel PN, Sigman M, Collura B, et al. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part I. *J Urol*. Jan 2021;205(1):36-43. doi:10.1097/ju.000000000001521
54. Gerull S, Medinger M, Heim D, Passweg J, Stern M. Evaluation of the Pretransplantation Workup before Allogeneic Transplantation. *Biology of Blood and Marrow Transplantation*. 2014/11/01/ 2014;20(11):1852-1856. doi:https://doi.org/10.1016/j.bbmt.2014.06.029

55. Kaste SC, Kaufman RA, Sunkara A, et al. Routine pre- and post-hematopoietic stem cell transplant computed tomography of the abdomen for detecting invasive fungal infection has limited value. *Biol Blood Marrow Transplant*. Jun 2015;21(6):1132-5.

doi:10.1016/j.bbmt.2015.02.023

56. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A Review of Von Hippel-Lindau Syndrome. *J Kidney Cancer VHL*. 2017;4(3):20-29. doi:10.15586/jkcvhl.2017.88
57. Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. *Front Endocrinol (Lausanne)*. 2019;10:339. doi:10.3389/fendo.2019.00339

58. American College of Radiology. ACR Appropriateness Criteria[®] Acute Pelvic Pain in the Reproductive Age Group. American College of Radiology. Updated 2015. Accessed December 28, 2022. https://acsearch.acr.org/docs/69503/narrative/

59. Kolon TF, Herndon CD, Baker LA, et al. Evaluation and treatment of cryptorchidism: AUA guideline. *J Urol*. Aug 2014;192(2):337-45. doi:10.1016/j.juro.2014.05.005

60. American College of Radiology. ACR Appropriateness Criteria® Abnormal Uterine Bleeding. American College of Radiology (ACR). Updated 2020. Accessed December 28, 2022. https://acsearch.acr.org/docs/69458/Narrative/

61. Deshmukh SP, Gonsalves CF, Guglielmo FF, Mitchell DG. Role of MR imaging of uterine leiomyomas before and after embolization. *Radiographics*. Oct 2012;32(6):E251-81. doi:10.1148/rg.326125517

62. Siegelman ES, Oliver ER. MR imaging of endometriosis: ten imaging pearls. *Radiographics*. Oct 2012;32(6):1675-91. doi:10.1148/rg.326125518

63. American College of Radiology. ACR Appropriateness Criteria® Female Infertility. American College of Radiology. Updated 2019. Accessed December 28, 2022.

https://acsearch.acr.org/docs/3093336/Narrative/

64. Cunningham RK, Horrow MM, Smith RJ, Springer J. Adenomyosis: A Sonographic Diagnosis. *Radiographics*. Sep-Oct 2018;38(5):1576-1589. doi:10.1148/rg.2018180080

65. Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ, Sisodia RC, Gervais DA, Lee SI. MRI of Placenta Accreta, Placenta Increta, and Placenta Percreta: Pearls and Pitfalls. *AJR Am J Roentgenol*. Jan 2017;208(1):214-221. doi:10.2214/ajr.16.16281

66. Kirkham A. MRI of the penis. *Br J Radiol*. Nov 2012;85 Spec No 1(Spec Iss 1):S86-93. doi:10.1259/bjr/63301362

67. Parker RA, 3rd, Menias CO, Quazi R, et al. MR Imaging of the Penis and Scrotum. *Radiographics*. Jul-Aug 2015;35(4):1033-50. doi:10.1148/rg.2015140161

68. Dwarkasing RS, Dinkelaar W, Hop WC, Steensma AB, Dohle GR, Krestin GP. MRI evaluation of urethral diverticula and differential diagnosis in symptomatic women. *AJR Am J Roentgenol*. Sep 2011;197(3):676-82. doi:10.2214/ajr.10.6144

69. Knuttinen MG, Xie K, Jani A, Palumbo A, Carrillo T, Mar W. Pelvic venous insufficiency: imaging diagnosis, treatment approaches, and therapeutic issues. *AJR Am J Roentgenol*. Feb 2015;204(2):448-58. doi:10.2214/ajr.14.12709

70. Buddha S, Menias CO, Katabathina VS. Imaging of urachal anomalies. *Abdom Radiol (NY)*. Dec 2019;44(12):3978-3989. doi:10.1007/s00261-019-02205-x

71. Parada Villavicencio C, Adam SZ, Nikolaidis P, Yaghmai V, Miller FH. Imaging of the Urachus: Anomalies, Complications, and Mimics. *Radiographics*. Nov-Dec 2016;36(7):2049-2063. doi:10.1148/rg.2016160062

72. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. *Am J Gastroenterol*. Aug 2014;109(8):1141-57; (Quiz) 1058. doi:10.1038/ajg.2014.190

73. Benn DE, Robinson BG, Clifton-Bligh RJ. 15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5. *Endocr Relat Cancer*. Aug 2015;22(4):T91-103. doi:10.1530/erc-15-0268

74. Hosseinzadeh K, Oto A, Allen BC, et al. ACR Appropriateness Criteria(®) Hematospermia. *J Am Coll Radiol*. May 2017;14(5s):S154-s159. doi:10.1016/j.jacr.2017.02.023



75. Davis DL, Morrison JJ. Hip Arthroplasty Pseudotumors: Pathogenesis, Imaging, and Clinical Decision Making. *J Clin Imaging Sci*. 2016;6:17. doi:10.4103/2156-7514.181493

76. Yanny S, Cahir JG, Barker T, et al. MRI of aseptic lymphocytic vasculitis-associated lesions in metal-on-metal hip replacements. *AJR Am J Roentgenol*. Jun 2012;198(6):1394-402. doi:10.2214/ajr.11.7504

77. Prayer D, Malinger G, Brugger PC, et al. ISUOG Practice Guidelines: performance of fetal magnetic resonance imaging. *Ultrasound Obstet Gynecol*. May 2017;49(5):671-680. doi:10.1002/uog.17412

78. ACR-SPR Practice Parameter for the Safe and Optimal Performance of Fetal Magnetic Resonance Imaging (MRI). American College of Radiology (ACR), Society for Pediatric Radiology (SPR). Updated 2020. Accessed December 28, 2022. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Fetal.pdf

79. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS[®] Prostate Imaging – Reporting and Data System Version 2.1. American College of Radiology (ACR). Updated 2019. Accessed December 28, 2022. https://www.acr.org/-/media/ACR/Files/RADS/PI-RADS/PIRADS-V2-1.pdf

80. Last AR, Hulbert K. Chronic low back pain: evaluation and management. *Am Fam Physician*. Jun 15 2009;79(12):1067-74.

81. American College of Radiology. ACR Appropriateness Criteria[®] Low Back Pain. American College of Radiology (ACR). Updated 2021. Accessed January 29, 2023.

https://acsearch.acr.org/docs/69483/Narrative/

Tasian GE, Copp HL, Baskin LS. Diagnostic imaging in cryptorchidism: utility, indications, and effectiveness. *J Pediatr Surg*. Dec 2011;46(12):2406-13. doi:10.1016/j.jpedsurg.2011.08.008
 Tahmasebi F, Nath R, Sokolovsky N, Scaoli J, Boley J, Mehra G. Incidental finding of raised CA125: a cause for concern. *Crit Care Obst Gyne*. 2018;5(01):1-5.

Page 23 of 31

ADDITIONAL RESOURCES

1. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. *N Engl J Med*. Mar 5 2020;382(10):917-928. doi:10.1056/NEJMoa1910038

2. Ahmed HU, El Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet*. Feb 25 2017;389(10071):815 822. doi:10.1016/s0140 6736(16)32401 1

3. Rosenkrantz AB, Verma S, Choyke PL, et al. Prostate MRI and MRI-Targeted Biopsy in Patients with Prior Negative Biopsy. American Urological Association (AUA). Updated 2016. Accessed <u>December 28, 2022</u>November 5, 2021. <u>Prostate MRI and MRI-Targeted Biopsy in</u> <u>Patients with Prior Negative Biopsy - American Urological Association (auanet.org)</u> <u>http://www.auanet.org/guidelines/prostate-mri-and-mri-targeted-biopsy</u>

 Behr SC, Courtier JL, Qayyum A. Imaging of müllerian duct anomalies. Radiographics. Oct 2012;32(6):E233-50. doi:10.1148/rg.326125515

<u>4</u>5. Bitti GT, Argiolas GM, Ballicu N, et al. Pelvic floor failure: MR imaging evaluation of anatomic and functional abnormalities. *Radiographics*. Mar-Apr 2014;34(2):429-48. doi:10.1148/rg.342125050

 Bloch BN, Lenkinski RE, Rofsky NM. The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach. *Cancer Biomark*. 2008;4(4-5):251-62. doi:10.3233/cbm-2008-44-507
 Brandon CJ, Jacobson JA, Fessell D, et al. Groin pain beyond the hip: how anatomy predisposes to injury as visualized by musculoskeletal ultrasound and MRI. *AJR Am J* Roentgenol. Nov 2011;197(5):1190-7. doi:10.2214/ajr.10.4890

<u>5</u>8. Jegannathan D, Indiran V. Magnetic resonance imaging of classified and unclassified Müllerian duct anomalies: Comparison of the American Society for Reproductive Medicine and the European Society of Human Reproduction and Embryology classifications. *SA J Radiol*. 2018;22(1):1259. doi:10.4102/sajr.v22i1.1259

<u>6</u>9. Jhaveri KS, Hosseini-Nik H. MRI of Rectal Cancer: An Overview and Update on Recent Advances. *AJR Am J Roentgenol*. Jul 2015;205(1):W42-55. doi:10.2214/ajr.14.14201 <u>7</u>10. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med*. May 10 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993

<u>8</u>11. Klotz L, Chin J, Black PC, et al. Comparison of Multiparametric Magnetic Resonance Imaging Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol*. Apr 1 2021;7(4):534-542. doi:10.1001/jamaoncol.2020.7589

 Koulouris G. Imaging review of groin pain in elite athletes: an anatomic approach to imaging findings. *AJR Am J Roentgenol*. Oct 2008;191(4):962-72. doi:10.2214/ajr.07.3410
 Lassandro F, Iasiello F, Pizza NL, et al. Abdominal hernias: Radiological features. *World J* Gastrointest Endosc. Jun 16 2011;3(6):110-7. doi:10.4253/wjge.v3.i6.110



<u>9</u>14. Li JJ, Chung JPW, Wang S, Li TC, Duan H. The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. *Biomed Res Int.* 2018;2018:6832685. doi:10.1155/2018/6832685

15. Marks L, Young S, Natarajan S. MRI ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. Jan 2013;23(1):43-50. doi:10.1097/MOU.0b013e32835ad3ee

106. Meermeier NP, Foster BR, Liu JJ, Amling CL, Coakley FV. Impact of Direct MRI Guided Biopsy of the Prostate on Clinical Management. *AJR Am J Roentgenol*. Aug 2019;213(2):371-376. doi:10.2214/ajr.18.21009

1<u>1</u>7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma: Cutaneous Version <u>1</u>2.202<u>3</u>1. National Comprehensive Cancer Network (NCCN). Updated <u>December 22</u>, <u>2022</u>February 19, 2021. Accessed <u>December 28</u>November 5, 202<u>2</u>1.

https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma Version
 3.2018. National Comprehensive Cancer Network (NCCN). Updated July 12, 2018. Accessed
 November 5, 2021. <u>https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf</u>
 1<u>12</u>9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Basal Cell Skin Cancer
 Version 2.202<u>2</u>1. National Comprehensive Cancer Network (NCCN). Updated <u>March 24,</u>
 February 25, 20221. Accessed November 15, 20221.

https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf

20. O'Malley RB, Al-Hawary MM, Kaza RK, Wasnik AP, Liu PS, Hussain HK. Rectal imaging: part 2, Perianal fistula evaluation on pelvic MRI—what the radiologist needs to know. *AJR Am J* Roentgenol. Jul 2012;199(1):W43–53. doi:10.2214/ajr.11.8361

21. Ostlere S. How to image metal-on-metal prostheses and their complications. *AJR Am J* Roentgenol. Sep 2011;197(3):558-67. doi:10.2214/ajr.11.6840

22. Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. *Urology*. Nov 2012;80(5):1075-9. doi:10.1016/j.urology.2012.07.040

<u>1</u>23. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. *Lancet Oncol*. Jan 2019;20(1):100-109. doi:10.1016/s1470-2045(18)30569-2

<u>1</u>24. Shoji S, Hiraiwa S, Endo J, et al. Manually controlled targeted prostate biopsy with realtime fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience. *Int J Urol*. Feb 2015;22(2):173–8. doi:10.1111/iju.12643 25. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med*. Jul 17 2003;349(3):215–24. doi:10.1056/NEJMoa030660

<u>15</u>26. Tosoian JJ, Chappidi M, Feng Z, et al. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. *BJU Int*. May 2017;119(5):676-683. doi:10.1111/bju.13573 <u>16</u>27. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global Review of Melanoma Follow-up Guidelines. *J Clin Aesthet Dermatol*. Sep 2013;6(9):18-26.



Page **25** of **31** Pelvis MRI <u>17</u>28. Wallis CJD, Haider MA, Nam RK. Role of mpMRI of the prostate in screening for prostate cancer. *Transl Androl Urol*. Jun 2017;6(3):464-471. doi:10.21037/tau.2017.04.31 <u>18</u>29. van der Leest M, Cornel E, Israël B, et al. Head to head Comparison of Transrectal Ultrasound guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance guided Biopsy in Biopsy naïve Men with Elevated Prostate specific Antigen: A Large Prospective Multicenter Clinical Study. *Eur Urol*. Apr 2019;75(4):570-578. doi:10.1016/j.eururo.2018.11.023

POLICY HISTORY

Date	Summary
March 2023	Prostate cancer: updated guidance based on new NCCN criteria
	IBD: clarified indications
	Hernia: added indication for deep pelvic hernia
	 Musculoskeletal: additional guidance provided for hip imaging,
	non-diagnostic requests added, corrected statement requiring
	abnormal x-ray to requiring prior x-ray
	• Other: specified guidance for weight loss, paraneoplastic syndrome,
	edema; added indications for thrombocytopenia, gestational
	trophoblastic disease, cancer predisposition syndromes
	Aneurysm: added section about non-aortic vascular disease
	Transplant: added section
	General Information moved to beginning of guideline with added
	statement on clinical indications not addressed in this guideline
	 Added statement regarding further evaluation of indeterminate
	findings on prior imaging
	 Aligned sections across body imaging guidelines
<u>March 2022</u>	Added when MRI is requested to potentially avoid a prostate
	biopsy
	Added abnormal incidental pelvic lymph nodes when follow-up is
	recommended based on prior imaging (initial 3-month follow-up)
	Within section concerning evaluation of suspected infection or
	inflammatory disease, added:
	 Suspected peritonitis (typically needing to include MRI Abd)
	with abd pain, tenderness to palpation, and at least one of the
	following:
	Rebound, guarding or rigid abdomen, OR
	Severe tenderness to palpation over entire
	<u>abdomen</u>
	 Complications of diverticulitis with severe abdominal pain or
	severe tenderness or mass, not responding to antibiotic

	treatment (prior imaging study is not required for diverticulitis
	diagnosis)
	Removed "For MR Enterography (MRE) if CT or MRI of the
	abdomen and pelvis are inconclusive" from the section on
	evaluation of suspected IBD
	• Clarified pelvic pain due to suspected occult, spigelian, or incisional
	hernia
	Clarified hernia with suspected complications
	Added "after initial x-ray" to Sacroiliac Joint Dysfunction
	Removed "For evaluation of suspected pelvic floor weakness in
	women with functional disorders, such as urinary or fecal
	incontinence, obstructed defecation, and pelvic organ prolapse"
	from "Other Indications for a Pelvic MRI"
	Added B symptoms to "Other Indications for a Pelvic MRI"
November 2021	Added +0698T
July 2021	
	prostate cancer) based on updates to Version 2.2021 NCCN
	guidelines and 2020 publication of updated AUA-SAR SOPs
	regarding MRI
April 2021	 Updated the initial imaging for prostate cancer to reflect 2021
	NCCN changes and "adjusted PSA"
	 <u>Revised indication for prostate MRI (suspected prostate cancer) to</u>
	clarify criteria related to a negative prior biopsy and added criteria
	for when imaging is appropriate prior to biopsy
	 Included criteria for ultrasound abnormalities for adenomyosis
	 Added limited circumstances when prior imaging is not needed
	before MRI for the evaluation of urethral diverticula
	Mention WRU Which includes WRI abo
	<u>Penanai instula including with Gronnis</u>
	Added section on MRE for IRD
	Added section on Lumbosacral playus, pudandal neuralgia
	<u>Added Section on Lumposacial piexus, pudendal neuraigia,</u>
	Added soparate section on hernia including sports hernia
	Added apportal uterine bleeding: adepomyosis: pelvic floor
	weakness: urachal anomalies: MR defecography: surveillance for
	paraganglioma syndromes: hematosnermia: LE edema: right
	varicocele: May-Thurner
	Added the Fetal MR GL to page

	Comment section on Lumbar plexopathy, sports hernia, elevated
	<u>CA 125</u>
June 2019	<u>Added the following indications:</u>
	 rising or persistent elevated PSA OR suspicious DRE and at
	least 15 years life expectancy and negative prior biopsy
	<u>suspected perianal fistula</u>
	<u>6 months time specification for f/u of known or suspected</u>
	post-operative complication involving hips or pelvis
	 for confirmed stress (fatigue) fracture for "return to play"
	evaluation
	 post operative complications after pelvic floor surgery
	For known prostate cancer: Initial treatment by active
	surveillance w/initial mpMRI and mpMRI to be repeated no
	more than every 12 months unless clinically indicated
	suspected placenta accrete or percreta when US is
	indeterminate
	<u>further assessment of a scrotal or penile mass when</u>
	ultrasound is inconclusive
	 investigation of a malfunctioning penile prosthesis
	 <u>suspected urethral diverticula and other imaging is</u>
	inconclusive
	 evaluation of adenomyosis when ultrasound is equivocal,
	especially in the case of suspected focal adenomyoma when it
	will help determine if surgery is indicated
	 <u>suspected pelvic congestion syndrome in patients with chronic</u>
	pelvic pain when other imaging is non-diagnostic
	<u>— suspected patent urachus when ultrasound is non diagnostic</u>
	evaluation of enlargement of organ abnormality seen on
	previous imaging - to provide an alternative to an
	Indeterminate or inconclusive ultrasound
	<u></u>
	 Home exercise program information updated to include dates
	and duration of failed PT and other

Page **28** of **31** Pelvis MRI



Page **29** of **31** Pelvis MRI



Reviewed / Approved by NIA Clinical Guideline Committee

Disclaimer: National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates ("NIA"). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.



GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates ("Magellan"). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and

